Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | TLR4 | O00206 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5180599 | 0.92 | THRB (0.71) | THRBCYP3A4CYP2C19CYP2C9TSHR | |
| SCHEMBL5181852 | 0.92 | THRB (0.71) | THRBCYP3A4CYP2C19CYP2C9TSHR | |
| SCHEMBL3340261 | 0.92 | THRB (0.71) | THRBCYP3A4CYP2C19CYP2C9TSHR | |
| SCHEMBL3228038 | 0.91 | THRB (0.69) | THRBCYP3A4CYP2C19CYP2C9TSHR | |
| SCHEMBL17775399 | 0.84 | THRB (0.67) | THRBCYP3A4CYP2C19CYP2C9KMT2A | |
| SCHEMBL5179358 | 0.83 | THRB (0.57) | THRBCYP3A4CYP2C19CYP2C9TSHR | |
| SCHEMBL5182268 | 0.83 | THRB (0.57) | THRBCYP3A4CYP2C19CYP2C9TSHR | |
| SCHEMBL5179351 | 0.83 | THRB (0.57) | THRBCYP3A4CYP2C19CYP2C9TSHR | |
| SCHEMBL2316488 | 0.81 | ALDH1A1 (0.55) | THRBTSHRALDH1A1L3MBTL1NPSR1 | |
| SCHEMBL16352666 | 0.81 | THRB (0.55) | THRBCYP3A4CYP2C19CYP2C9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9790234-B2 | IRAK inhibitors and uses thereof | NIMBUS IRIS, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-20170081340-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS INC (US) | 2017-03-23 | — | — | US | disclosed |
| US-9481687-B2 | IRAK inhibitors and uses thereof | NIMBUS IRIS, INC. (US) | 2016-11-01 | — | — | US | disclosed |
| US-20160193216-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. | 2016-07-07 | — | — | US | disclosed |
| US-20160002257-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. | 2016-01-07 | — | — | US | disclosed |
| US-9212190-B2 | IRAK inhibitors and uses thereof | NIMBUS IRIS, INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-9085586-B2 | IRAK inhibitors and uses thereof | NIMBUS IRIS, INC. (US) | 2015-07-21 | — | — | US | disclosed |
| US-8809373-B2 | Pyridine non-classical cannabinoid compounds and related methods of use | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2014-08-19 | — | — | US | disclosed |
| US-20140018343-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. | 2014-01-16 | — | — | US | disclosed |
| US-20130231328-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130123304-A1 | PYRIDINE NON-CLASSICAL CANNABINOID COMPOUNDS AND RELATED METHODS OF USE | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002257-A1 | IRAK INHIBITORS AND USES THEREOF | IRAK4, IRAK2, IRAK1 | THRB 1091/4885CYP3A4 3554/4885CYP2C19 4163/4885 |
| US-20160193216-A1 | IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | THRB 1387/4885CYP3A4 4509/4885CYP2C19 4723/4885 |
| US-20170081340-A1 | IRAK INHIBITORS AND USES THEREOF | IRAK4, IRAK2, IRAK1 | THRB 1091/4885CYP3A4 3554/4885CYP2C19 4163/4885 |
| US-20130123304-A1 | PYRIDINE NON-CLASSICAL CANNABINOID COMPOUNDS AND RELATED METHODS OF USE | CNR1, CNR2, NPY1R | THRB 1152/4885CYP3A4 548/4885CYP2C19 423/4885 |
| US-20130231328-A1 | IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | THRB 1387/4885CYP3A4 4509/4885CYP2C19 4723/4885 |
| US-20140018343-A1 | IRAK INHIBITORS AND USES THEREOF | IRAK4, IRAK2, IRAK1 | THRB 1091/4885CYP3A4 3554/4885CYP2C19 4163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.